Search

Your search keyword '"Jonasch, E"' showing total 652 results

Search Constraints

Start Over You searched for: Author "Jonasch, E" Remove constraint Author: "Jonasch, E"
652 results on '"Jonasch, E"'

Search Results

3. 1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study.

4. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

5. LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study

17. 678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)

20. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 41 countries

21. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

22. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

23. Response to correspondence on 'Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation'.

24. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care

29. Definitive Radiotherapy for Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation

30. 715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC)

31. LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease

32. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

33. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

34. Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation.

36. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)

39. Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience

40. Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study

41. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

42. Kniegelenk und Unterschenkel

44. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

46. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

47. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy

48. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

49. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

50. Testicular Cancer

Catalog

Books, media, physical & digital resources